Global expansion Clever Leaves has shifted operations and partnerships across Colombia, Europe, and Australia, signaling openness to B2B opportunities and licensed production collaborations in multiple regions for cannabinoid APIs and finished products.

Sustainability edge The company emphasizes ESG-friendly, low-cost, industrial-scale production with recognition for carbon neutrality, presenting a compelling sustainability story to customers and partners seeking responsible supply chains.

Strategic partnerships Recent alliances with Australian Natural Therapeutics Group and historical licensing deals with Ethypharm indicate a strong channel strategy and potential for co-developed or licensed product opportunities in key markets.

Regulatory readiness Operating as a licensed producer with pharmaceutical-grade standards and certifications positions Clever Leaves to pursue regulated markets requiring compliant supply of cannabis-derived APIs and finished products.

Growth through sale of assets Partial asset divestment in 2023 and reorganizations suggest flexibility to reallocate resources toward higher-growth geographies or product lines, presenting targeted upsell or renewal opportunities with existing customers and new markets.